Natera (NTRA)
(Delayed Data from NSDQ)
$105.52 USD
+2.19 (2.12%)
Updated May 14, 2024 04:00 PM ET
After-Market: $105.22 -0.30 (-0.28%) 7:58 PM ET
2-Buy of 5 2
F Value A Growth F Momentum C VGM
Natera (NTRA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Downside to Average Price Target |
---|---|---|---|
$102.13 | $130.00 | $70.00 | -1.16% |
Price Target
Based on short-term price targets offered by 16 analysts, the average price target for Natera comes to $102.13. The forecasts range from a low of $70.00 to a high of $130.00. The average price target represents a decline of 1.16% from the last closing price of $103.33.
Analyst Price Targets (16)
Broker Rating
Natera currently has an average brokerage recommendation (ABR) of 1.09 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 16 brokerage firms. The current ABR compares to an ABR of 1.09 a month ago based on 16 recommendations.
Of the 16 recommendations deriving the current ABR, 14 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 87.5% and 12.5% of all recommendations. A month ago, Strong Buy made up 87.5%, while Buy represented 12.5%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 14 | 14 | 14 | 12 | 11 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 0 | 0 | 0 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.09 | 1.09 | 1.09 | 1.23 | 1.25 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/10/2024 | Canaccord Genuity | Kyle Mikson | Strong Buy | Strong Buy |
4/12/2024 | SVB Securities | Puneet Souda | Strong Buy | Strong Buy |
4/8/2024 | Craig-Hallum | William B Bonello | Not Available | Strong Buy |
3/6/2024 | Piper Sandler | David M Westenberg | Strong Buy | Strong Buy |
2/28/2024 | Robert W. Baird & Co. | Catherine W Schulte | Strong Buy | Strong Buy |
2/20/2024 | Raymond James | Andrew Cooper | Strong Buy | Moderate Buy |
1/30/2024 | Stephens | Mason Carrico | Strong Buy | Strong Buy |
12/29/2023 | BTIG | Mark Massaro | Not Available | Strong Buy |
12/14/2023 | Guggenheim Securities | Subbu Nambi | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.09 |
ABR (Last week) | 1.09 |
# of Recs in ABR | 16 |
Average Target Price | $102.13 |
LT Growth Rate | NA |
Industry | Medical Services |
Industry Rank by ABR | 90 of 252 |
Current Quarter EPS Est: | -0.63 |